Immune checkpoints are regulatory pathways that preserve immune tolerance and limit excessive inflammation. Although they have been studied extensively in oncology, growing evidence indicates that checkpoint signaling also influences brain development, synaptic function, neuroendocrine regulation, and the balance between neuroprotection and neuroinflammation. Alterations in pathways involving programmed cell death protein 1, programmed death ligand 1, cytotoxic T-lymphocyte-associated antigen 4, lymphocyte activation gene 3, T-cell immunoglobulin and mucin-domain containing 3, and related mediators have been described in autoimmune encephalitis, multiple sclerosis, neurodegenerative disease, mood disorders, psychotic disorders, and treatment-related neuropsychiatric syndromes. Immune checkpoint inhibitors used for cancer may provoke immune-related adverse events affecting cognition, mood, behavior, sleep, peripheral nerves, skeletal muscle, and the central nervous system. Conversely, endogenous checkpoint mechanisms may represent therapeutic targets for selected inflammatory or neuropsychiatric conditions. This review summarizes the epidemiology, biological mechanisms, risk factors, clinical manifestations, diagnostic approach, treatment principles, emerging therapies, and practical guideline considerations relevant to immune checkpoints in neuropsychiatric disorders.
The central nervous system was historically considered relatively isolated from systemic immunity, but contemporary neuroimmunology demonstrates continuous communication among immune cells, glial populations, endothelial barriers, peripheral organs, and neural circuits. Immune checkpoints are inhibitory or stimulatory receptor-ligand systems that regulate immune-cell activation, tissue tolerance, and resolution of inflammation. In the brain, these pathways participate in microglial surveillance, maintenance of the blood-brain barrier, synaptic remodeling, neuronal survival, and control of adaptive immune entry into neural tissue.
The clinical relevance of checkpoint biology has increased substantially with the widespread use of immune checkpoint inhibitors, including antibodies directed against programmed cell death protein 1, programmed death ligand 1, and cytotoxic T-lymphocyte-associated antigen 4. These agents improve survival in many malignancies but can produce neurological and psychiatric immune-related adverse events. At the same time, observational and experimental research suggests that dysregulated checkpoint signaling may contribute to psychiatric symptoms and inflammatory neurological disease independently of cancer therapy. Understanding this intersection is important for neurologists, psychiatrists, oncologists, internists, and emergency clinicians who evaluate new cognitive, behavioral, or neurological symptoms in patients receiving immunomodulatory treatment.
Neurological immune-related adverse events associated with checkpoint inhibition are uncommon compared with dermatological, gastrointestinal, endocrine, and pulmonary toxicities, but their consequences may be severe. Reported neurological complications include encephalitis, meningitis, myelitis, hypophysitis with neuroendocrine consequences, peripheral neuropathy, polyradiculoneuropathy, myasthenia gravis, myositis, cerebellar syndromes, and seizures. Psychiatric manifestations may occur as part of encephalitis or endocrine toxicity and can include delirium, agitation, depression, anxiety, insomnia, psychosis, personality change, and suicidal thinking. The incidence varies across studies because definitions, ascertainment methods, cancer populations, and treatment combinations differ.
In the general population, neuropsychiatric disorders impose a substantial burden through disability, impaired occupational function, caregiver stress, hospitalization, and premature mortality. Inflammatory mechanisms are not sufficient to explain all cases, but immune abnormalities are increasingly recognized as biologically relevant subgroups. Patients with autoimmune disease, prior neurological illness, or cancer-related treatment exposure may have overlapping causes of symptoms, making accurate attribution especially important. Even rare checkpoint-associated syndromes deserve attention because delayed recognition can lead to irreversible neurological injury, respiratory compromise, or prolonged functional decline.
Checkpoint pathways maintain immune equilibrium by modulating T-cell receptor signaling, co-stimulation, cytokine production, and lymphocyte trafficking. Programmed cell death protein 1 signaling generally reduces T-cell activity after ligand engagement and supports peripheral tolerance. Cytotoxic T-lymphocyte-associated antigen 4 limits early T-cell activation, primarily in lymphoid tissues. Additional inhibitory pathways, including lymphocyte activation gene 3, T-cell immunoglobulin and mucin-domain containing 3, and the immunoglobulin superfamily member B7-H3, contribute to exhaustion, tolerance, and tissue protection.
Within the nervous system, microglia express multiple checkpoint-related molecules and respond to neuronal injury, infection, metabolic stress, and altered synaptic activity. Excessive inflammatory signaling can increase glutamate toxicity, impair oligodendrocyte function, disrupt the blood-brain barrier, and alter monoaminergic and hypothalamic-pituitary-adrenal pathways. These processes may affect attention, motivation, sleep, mood, and executive function. Conversely, excessive immune suppression may impair pathogen surveillance or permit persistent pathological immune activity. The biological effects are therefore context-dependent rather than uniformly beneficial or harmful.
Checkpoint blockade can break established immune tolerance through expansion of autoreactive T cells, activation of previously quiescent clones, increased antigen presentation, and antibody-mediated injury. Some neurological syndromes resemble classical autoimmune diseases, whereas others have distinctive features linked to cancer-associated autoimmunity. Neural antigens released by tumors may generate immune responses that cross-react with peripheral or central nervous system structures. Cytokine amplification, complement activation, and disruption of the blood-brain barrier may further intensify tissue damage.
Important risk factors include combination checkpoint therapy, previous exposure to neurotoxic chemotherapy or radiotherapy, pre-existing autoimmune disease, prior neurological or psychiatric illness, older age, systemic infection, and the presence of neuronal or neuromuscular autoantibodies. Patients with a history of myasthenia gravis, inflammatory neuropathy, multiple sclerosis, autoimmune encephalitis, or paraneoplastic neurological disease require individualized assessment before checkpoint treatment. Concurrent myositis or myocarditis can increase the danger of neuromuscular respiratory failure in patients who develop myasthenic symptoms.
Risk assessment should also consider medication interactions and alternative explanations. Corticosteroid exposure, opioid analgesics, sedative drugs, anticholinergic agents, metabolic abnormalities, sleep deprivation, uncontrolled pain, and cancer progression may mimic or worsen neuropsychiatric toxicity. A history of bipolar disorder, psychosis, trauma-related illness, or substance use does not exclude an immune-mediated process; a new, atypical, rapidly progressive, or treatment-linked presentation should prompt medical investigation rather than premature psychiatric attribution.
Clinical manifestations range from mild cognitive slowing and fatigue to fulminant encephalitis, seizures, coma, and autonomic instability. Encephalitis may present with short-term memory loss, confusion, altered personality, hallucinations, aphasia, seizures, or sleep disruption. Meningeal inflammation can cause headache, photophobia, fever, and neck stiffness. Myelitis may produce weakness, sensory changes, sphincter dysfunction, and a defined spinal sensory level. Peripheral involvement can result in paresthesia, pain, areflexia, cranial neuropathies, or rapidly progressive weakness.
Psychiatric symptoms may be prominent and include new-onset mania, severe anxiety, depression, disorganized behavior, catatonia, emotional lability, or psychosis. These symptoms may precede objective neurological findings. Endocrine toxicities, particularly hypophysitis, adrenal insufficiency, and thyroid dysfunction, can cause fatigue, impaired concentration, depression, delirium, or reduced motivation. Clinicians should identify red flags such as seizures, fluctuating consciousness, focal deficits, dysautonomia, fever, abnormal movements, rapid progression, or coexisting neuromuscular weakness.
Diagnosis is clinical and requires exclusion of competing causes while assessing temporal relationships to immunotherapy. Initial evaluation should include a detailed neurological and psychiatric examination, medication review, cancer history, immune-treatment schedule, and assessment of systemic symptoms. Laboratory testing commonly includes complete blood count, metabolic profile, liver and renal function, glucose, inflammatory markers when appropriate, thyroid studies, cortisol, and targeted infectious investigations. Vitamin deficiencies, toxic exposures, organ failure, and metabolic encephalopathy should be addressed.
Magnetic resonance imaging of the brain and, when indicated, the spinal cord can identify inflammatory lesions, edema, infarction, leptomeningeal disease, or alternative structural diagnoses, although imaging may be normal. Cerebrospinal fluid analysis may demonstrate pleocytosis, elevated protein, intrathecal immune activity, or infection. Electroencephalography is useful for detecting nonconvulsive seizures and diffuse encephalopathy. Serum and cerebrospinal fluid testing for neuronal surface and intracellular antibodies may support autoimmune or paraneoplastic diagnoses, but negative results do not exclude an immune-mediated syndrome. Lumbar puncture, neurophysiology, endocrine testing, and cardiac or respiratory assessment should be selected according to the clinical phenotype.
Management depends on severity and should involve oncology, neurology, psychiatry, endocrinology, infectious disease, and intensive care specialists when appropriate. For suspected moderate or severe neurological immune-related toxicity, checkpoint therapy is generally withheld while urgent evaluation proceeds. Severe or rapidly progressive presentations commonly require high-dose corticosteroids after appropriate infection assessment, with gradual tapering guided by clinical response. Intravenous immunoglobulin or plasma exchange may be considered for encephalitis, myasthenic syndromes, inflammatory neuropathy, or other steroid-refractory conditions. Rituximab or other immunosuppressive strategies may be used in selected cases after specialist consultation.
Supportive care is essential. Seizures require antiseizure treatment, delirium requires environmental and medical stabilization, and respiratory weakness requires serial pulmonary-function assessment and early ventilatory support. Psychiatric medications may be useful for severe agitation, insomnia, depression, or psychosis, but clinicians should consider drug interactions, QT prolongation, seizure threshold, anticholinergic burden, and the possibility that symptoms reflect encephalitis or endocrine failure. Hormone replacement is required for persistent adrenal, thyroid, or other pituitary deficiencies. Rechallenge with checkpoint therapy should be considered only after multidisciplinary review, complete or substantial recovery, assessment of cancer benefit, and careful evaluation of recurrence risk.
Research is moving toward biomarker-guided identification of patients who are vulnerable to checkpoint-related neuropsychiatric complications. Candidate biomarkers include autoantibody profiles, T-cell receptor signatures, cytokine patterns, soluble checkpoint molecules, neurofilament light chain, and markers of blood-brain barrier injury. Their clinical utility remains under investigation, and none should currently replace careful clinical assessment. Advanced neuroimaging, digital cognitive monitoring, and longitudinal patient-reported outcomes may improve early detection of subtle changes.
Experimental therapeutic approaches include selective cytokine inhibition, targeted B-cell depletion, modulation of microglial activation, and restoration of regulatory T-cell function. Research on the gut-brain axis is also evaluating whether microbiome composition influences immunotherapy response and neurotoxicity. In primary psychiatric disorders, checkpoint-related interventions remain investigational and should not be used outside appropriately governed clinical studies. The complexity of immune signaling means that broad suppression may reduce inflammation while increasing infection risk, impairing tumor control, or worsening metabolic and psychiatric outcomes.
Current clinical guidance supports baseline documentation of neurological and psychiatric history before initiating checkpoint therapy, with explicit education about confusion, seizures, weakness, sensory symptoms, mood changes, and behavioral disturbances. New or worsening symptoms should prompt early communication among the treating oncology team and relevant specialists. Severity grading should reflect functional impairment, objective neurological findings, respiratory or autonomic involvement, and the need for hospitalization rather than relying solely on symptom descriptions.
For suspected encephalitis, recommended evaluation generally includes brain imaging, cerebrospinal fluid studies, electroencephalography, infectious testing, metabolic assessment, and autoimmune or paraneoplastic investigations when clinically appropriate. Immunotherapy should be interrupted for significant toxicity, and corticosteroid treatment should not be unnecessarily delayed in a rapidly deteriorating patient after reasonable exclusion of immediately treatable infection. Long steroid tapers and escalation to intravenous immunoglobulin, plasma exchange, or additional immunosuppression should be individualized. Rechallenge requires a documented risk-benefit discussion, informed consent, and a monitoring plan. All cases should be reported through institutional pharmacovigilance systems to strengthen evidence on rare events.
Immune checkpoints are important regulators of neural immune tolerance and may influence both disease biology and treatment-related neuropsychiatric toxicity. Their disruption can produce diverse syndromes involving cognition, mood, behavior, seizures, meninges, spinal cord, peripheral nerves, neuromuscular junctions, and endocrine systems. Early recognition depends on maintaining a broad differential diagnosis, identifying red flags, and integrating neurological, psychiatric, oncological, infectious, metabolic, and endocrine assessments. Prompt interruption of offending therapy, specialist-guided immunosuppression, and intensive supportive care can improve outcomes in serious cases. Future progress will depend on validated biomarkers, clearer phenotypic classification, prospective registries, and trials of targeted immune modulation that preserve anticancer efficacy while reducing neurological and psychiatric harm.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation